Novel methods to rationally design vaccines include control by microRNAs (miRNAs) or zinc finger nucleases (ZFNs) . While each of these may be useful against persistent or latent viruses, miRNAs and ZFNs are limited to RNA and non-integrating DNA viruses respectively (Lauring et al., 2010) . Two other approaches have been recently proposed. In one approach, increased replication fidelity of errorprone RNA polymerases through mutations, reduces the likelihood of reversion from attenuation to wild type (Vignuzzi et al., 2008) . A second approach, dubbed synthetic attenuated virus engineering (SAVE), can be used to create non-virulent strains of viruses, which could provide a platform technology for vaccine development against a wide variety of viral diseases (Coleman et al., 2008; Wimmer et al., 2009; Mueller et al., 2010) . The new vaccine strategy exploits the fact that the genetic code is degenerate in that most amino acids are encoded by more than one three-nucleotide codon (e.g. GCA, GCC, GCG, and GCT all code for the amino acid alanine). Many organisms, including viruses, tend to have biases toward certain synonymous codons (the "codon bias") and codon pairs (the "codon pair bias") in their genes (Gutman and Hatfield, 1989; Moura et al., 2007; Tats et al., 2008) . Codon pair bias refers to the preferential pairing of certain codons over others (e.g. in human genes the codon pair GCC-GAA encodes the adjacent amino acids alanine-glutamic acid less often than GCA-GAG, even though GCC and GAA are the most used codons, Coleman et al., 2008) . Unfavourable host codon pairs introduced into a viral genome may adversely affect protein translation and thereby provide a method for producing attenuated viruses.
As a proof of concept for SAVE, a team led by Eckard Wimmer at Stony Brook University used a computer-guided approach to design weakened poliovirus strains (Coleman et al., 2008) . The research is an outgrowth of a technique they pioneered to assemble the virus from scratch (Cello et al., 2002) . The single stranded positive-sense RNA genome of poliovirus contains a long open reading frame encoding a polyprotein that is cleaved into P1 (capsid precursor), P2 and P3 (precursors to nonstructural proteins) flanked by 5' and 3' nontranslated regions. Briefly, they engineered the P1 coding region (encoding the viral capsid, 2643 nucleotides) with under-or over-represented codon pairs: the attenuated strains caused decreased rates of protein translation and protected mice challenged with a lethal dose of wild-type poliovirus (Figures 1 & 2, vide infra) . The promising results of this work suggested that SAVE could play a role in creating new vaccines for influenza virus. The "flu" virus genome is composed of eight segments of negative-sense RNA that encode up to 12 proteins. Segments targeted for attenuation encode proteins that play important roles in replication and assembly of influenza virus -nucleoprotein (NP), polymerase subunit B1(PB1), and hemagglutinin (HA). Synthetic strains of influenza virus PR8 containing one (NP, HA, or PB1), two (NP/HA or HA/PB1) or three (PB1/NP/HA, short PR8 3F ) codon pair deoptimized gene segments formed plaques and grew in vitro. The PR8 3F strain was highly attenuated in vivo and could protect mice challenged with wild-type influenza virus (Mueller et al., 2010) .
As a general strategy for vaccine development, SAVE offers several advantages. First, because this approach involves the introduction of hundreds of "silent" mutations, unlike the handful of mutations found in current vaccine strains, the probability of reversion of codon-pair deoptimized vaccines to virulence is essentially zero. Second, given the changes do not alter the amino acid sequences, the proteins expressed are identical to wild type virus and possess identical immunogenic properties. Finally, as attenuation is systematic rather than empiric, it can be applied speedily to a wide range of viruses in various species.
